标题
Highlights of the Latest Advances in Research on CDK Inhibitors
作者
关键词
-
出版物
Cancers
Volume 6, Issue 4, Pages 2224-2242
出版商
MDPI AG
发表日期
2014-10-27
DOI
10.3390/cancers6042224
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- 14-3-3 Binding to Cyclin Y contributes to cyclin Y/CDK14 association
- (2014) S. Li et al. ACTA BIOCHIMICA ET BIOPHYSICA SINICA
- ALS2CR7 (CDK15) attenuates TRAIL induced apoptosis by inducing phosphorylation of survivin Thr34
- (2014) Mi Hee Park et al. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
- Clinical study of the novel cyclin-dependent kinase inhibitor dinaciclib in combination with rituximab in relapsed/refractory chronic lymphocytic leukemia patients
- (2014) Claire Fabre et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Phase I Trial of Bortezomib (PS-341; NSC 681239) and "Nonhybrid" (Bolus) Infusion Schedule of Alvocidib (Flavopiridol; NSC 649890) in Patients with Recurrent or Refractory Indolent B-cell Neoplasms
- (2014) B. Holkova et al. CLINICAL CANCER RESEARCH
- CR8, a Novel Inhibitor of CDK, Limits Microglial Activation, Astrocytosis, Neuronal Loss, and Neurologic Dysfunction after Experimental Traumatic Brain Injury
- (2014) Shruti V Kabadi et al. JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM
- Discovery of 8-Cyclopentyl-2-[4-(4-methyl-piperazin-1-yl)-phenylamino]-7-oxo-7,8-dihydro-pyrido[2,3-d]pyrimidine-6-carbonitrile (7x) as a Potent Inhibitor of Cyclin-Dependent Kinase 4 (CDK4) and AMPK-Related Kinase 5 (ARK5)
- (2014) M. V. Ramana Reddy et al. JOURNAL OF MEDICINAL CHEMISTRY
- Preclinical Evaluation of AMG 925, a FLT3/CDK4 Dual Kinase Inhibitor for Treating Acute Myeloid Leukemia
- (2014) K. Keegan et al. MOLECULAR CANCER THERAPEUTICS
- Cdk5 inhibitor roscovitine alleviates neuropathic pain in the dorsal root ganglia by downregulating N-methyl-d-aspartate receptor subunit 2A
- (2014) Lei Yang et al. NEUROLOGICAL SCIENCES
- Fragment based discovery of arginine isosteres through REPLACE: Towards non-ATP competitive CDK inhibitors
- (2013) Padmavathy Nandha Premnath et al. BIOORGANIC & MEDICINAL CHEMISTRY
- A phase I trial of flavopiridol in relapsed multiple myeloma
- (2013) Craig C. Hofmeister et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Clinical and laboratory studies of the novel cyclin-dependent kinase inhibitor dinaciclib (SCH 727965) in acute leukemias
- (2013) Ivana Gojo et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- The Lab Oddity Prevails: Discovery of Pan-CDK Inhibitor (R)-S-Cyclopropyl-S-(4-{[4-{[(1R,2R)-2-hydroxy-1-methylpropyl]oxy}-5-(trifluoromethyl)pyrimidin-2-yl]amino}phenyl)sulfoximide (BAY 1000394) for the Treatment of Cancer
- (2013) Ulrich Lücking et al. ChemMedChem
- Randomized Phase II Trial of the Cyclin-Dependent Kinase Inhibitor Dinaciclib (MK-7965) Versus Capecitabine in Patients With Advanced Breast Cancer
- (2013) Monica M. Mita et al. Clinical Breast Cancer
- ATP-noncompetitive CDK inhibitors for cancer therapy: an overview
- (2013) Agnese Anna Abate et al. EXPERT OPINION ON INVESTIGATIONAL DRUGS
- Phase II Trial of the CDK4 Inhibitor PD0332991 in Patients With Advanced CDK4-Amplified Well-Differentiated or Dedifferentiated Liposarcoma
- (2013) Mark A. Dickson et al. JOURNAL OF CLINICAL ONCOLOGY
- The Cdk inhibitor flavopiridol enhances temozolomide-induced cytotoxicity in human glioma cells
- (2013) Takuro Hayashi et al. JOURNAL OF NEURO-ONCOLOGY
- A first-in-human, phase 1, dose-escalation study of dinaciclib, a novel cyclin-dependent kinase inhibitor, administered weekly in subjects with advanced malignancies
- (2013) John J Nemunaitis et al. Journal of Translational Medicine
- Small-molecule multi-targeted kinase inhibitor RGB-286638 triggers P53-dependent and -independent anti-multiple myeloma activity through inhibition of transcriptional CDKs
- (2013) D Cirstea et al. LEUKEMIA
- Cyclophosphamide, alvocidib (flavopiridol), and rituximab, a novel feasible chemoimmunotherapy regimen for patients with high-risk chronic lymphocytic leukemia
- (2013) Deborah M. Stephens et al. LEUKEMIA RESEARCH
- Randomized phase 2 study of the cyclin-dependent kinase inhibitor dinaciclib (MK-7965) versus erlotinib in patients with non-small cell lung cancer
- (2013) Joe J. Stephenson et al. LUNG CANCER
- PD-0332991, a CDK4/6 Inhibitor, Significantly Prolongs Survival in a Genetically Engineered Mouse Model of Brainstem Glioma
- (2013) Kelly L. Barton et al. PLoS One
- Phase I trial of the combination of flavopiridol and imatinib mesylate in patients with Bcr-Abl+ hematological malignancies
- (2012) Prithviraj Bose et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Effect of aprepitant on the pharmacokinetics of the cyclin-dependent kinase inhibitor dinaciclib in patients with advanced malignancies
- (2012) Da Zhang et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- CDK inhibitors R-roscovitine and S-CR8 effectively block renal and hepatic cystogenesis in an orthologous model of ADPKD
- (2012) Nikolay O. Bukanov et al. CELL CYCLE
- The Cyclin-Dependent Kinase Inhibitor Flavopiridol Potentiates Doxorubicin Efficacy in Advanced Sarcomas: Preclinical Investigations and Results of a Phase I Dose-Escalation Clinical Trial
- (2012) J. J. Luke et al. CLINICAL CANCER RESEARCH
- A Phase 2 Trial of Flavopiridol (Alvocidib) and Cisplatin in Platin-Resistant Ovarian and Primary Peritoneal Carcinoma: MC0261
- (2012) Keith C. Bible et al. GYNECOLOGIC ONCOLOGY
- Flavopiridol treatment of patients aged 70 or older with refractory or relapsed chronic lymphocytic leukemia is a feasible and active therapeutic approach
- (2012) D. M. Stephens et al. HAEMATOLOGICA
- AZD5438, an Inhibitor of Cdk1, 2, and 9, Enhances the Radiosensitivity of Non-Small Cell Lung Carcinoma Cells
- (2012) Pavithra Raghavan et al. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
- Effect of Mimetic CDK9 Inhibitors on HIV-1-Activated Transcription
- (2012) Rachel Van Duyne et al. JOURNAL OF MOLECULAR BIOLOGY
- Outcome of patients with relapsed or refractory chronic lymphocytic leukemia treated with flavopiridol: impact of genetic features
- (2012) J A Woyach et al. LEUKEMIA
- Chemistry and Biology of Fascaplysin, a Potent Marine-Derived CDK-4 Inhibitor
- (2012) S. B. Bharate et al. MINI-REVIEWS IN MEDICINAL CHEMISTRY
- CDK-4 Inhibitor P276 Sensitizes Pancreatic Cancer Cells to Gemcitabine-Induced Apoptosis
- (2012) D. Subramaniam et al. MOLECULAR CANCER THERAPEUTICS
- Cyclin-dependent kinase inhibitors move into Phase III
- (2012) Malini Guha NATURE REVIEWS DRUG DISCOVERY
- Prevention of Radiation-Induced Salivary Gland Dysfunction Utilizing a CDK Inhibitor in a Mouse Model
- (2012) Katie L. Martin et al. PLoS One
- Cyclin K goes with Cdk12 and Cdk13
- (2012) Jiri Kohoutek et al. Cell Division
- Intrinsic caspase-8 activation mediates sensitization of erlotinib-resistant tumor cells to erlotinib/cell-cycle inhibitors combination treatment
- (2012) M Orzáez et al. Cell Death & Disease
- Development of a time-resolved fluorescence resonance energy transfer assay for cyclin-dependent kinase 4 and identification of its ATP-noncompetitive inhibitors
- (2011) Mei-Chu Lo et al. ANALYTICAL BIOCHEMISTRY
- Fluorescent cyclin-dependent kinase inhibitors block the proliferation of human breast cancer cells
- (2011) Venkata Mahidhar Yenugonda et al. BIOORGANIC & MEDICINAL CHEMISTRY
- First BRET-based screening assay performed in budding yeast leads to the discovery of CDK5/p25 interaction inhibitors
- (2011) Caroline Corbel et al. Biotechnology Journal
- Phase 1 and pharmacokinetic study of bolus-infusion flavopiridol followed by cytosine arabinoside and mitoxantrone for acute leukemias
- (2011) J. E. Karp et al. BLOOD
- A first in man, phase I dose-escalation study of PHA-793887, an inhibitor of multiple cyclin-dependent kinases (CDK2, 1 and 4) reveals unexpected hepatotoxicity in patients with solid tumors
- (2011) Christophe Massard et al. CELL CYCLE
- Phase I Trial of Bortezomib (PS-341; NSC 681239) and Alvocidib (Flavopiridol; NSC 649890) in Patients with Recurrent or Refractory B-Cell Neoplasms
- (2011) B. Holkova et al. CLINICAL CANCER RESEARCH
- Phase I, Dose-Escalation Trial of the Oral Cyclin-Dependent Kinase 4/6 Inhibitor PD 0332991, Administered Using a 21-Day Schedule in Patients with Advanced Cancer
- (2011) K. T. Flaherty et al. CLINICAL CANCER RESEARCH
- The CDK inhibitors in cancer research and therapy
- (2011) Jonas Cicenas et al. JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
- CR8, a Selective and Potent CDK Inhibitor, Provides Neuroprotection in Experimental Traumatic Brain Injury
- (2011) Shruti V. Kabadi et al. Neurotherapeutics
- A Phase I Study of Flavopiridol in Combination With Gemcitabine and Irinotecan in Patients With Metastatic Cancer
- (2010) Houman M. Fekrazad et al. AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS
- Phase I clinical and pharmacokinetic study of a novel schedule of flavopiridol in relapsed or refractory acute leukemias
- (2010) W. Blum et al. HAEMATOLOGICA
- Cyclin D3/CDK11p58 Complex Involved in Schwann Cells Proliferation Repression Caused by Lipopolysaccharide
- (2010) Yinong Duan et al. INFLAMMATION
- A phase I pharmacokinetic study of pulse-dose vorinostat with flavopiridol in solid tumors
- (2010) Mark Andrew Dickson et al. INVESTIGATIONAL NEW DRUGS
- Phase I Study of Flavopiridol with Oxaliplatin and Fluorouracil/Leucovorin in Advanced Solid Tumors
- (2009) D. Rathkopf et al. CLINICAL CANCER RESEARCH
- Phase II Study of Flavopiridol in Relapsed Chronic Lymphocytic Leukemia Demonstrating High Response Rates in Genetically High-Risk Disease
- (2009) Thomas S. Lin et al. JOURNAL OF CLINICAL ONCOLOGY
- Functional Evolution of Cyclin-Dependent Kinases
- (2009) John H. Doonan et al. MOLECULAR BIOTECHNOLOGY
- Cyclin-dependent kinases: a family portrait
- (2009) Marcos Malumbres et al. NATURE CELL BIOLOGY
- A Phase II Study of Flavopiridol (Alvocidib) in Combination with Docetaxel in Refractory, Metastatic Pancreatic Cancer
- (2009) Richard D. Carvajal et al. PANCREATOLOGY
- Clinical response and pharmacokinetics from a phase 1 study of an active dosing schedule of flavopiridol in relapsed chronic lymphocytic leukemia
- (2008) M. A. Phelps et al. BLOOD
- An Unusual Member of the Cdk Family: Cdk5
- (2008) Fatema A. Dhariwala et al. CELLULAR AND MOLECULAR NEUROBIOLOGY
- Phase I Study of Flavopiridol in Combination with Paclitaxel and Carboplatin in Patients with Non–Small-Cell Lung Cancer
- (2008) Saby George et al. Clinical Lung Cancer
- Characterization of Cyclin L1 and L2 Interactions with CDK11 and Splicing Factors
- (2008) Pascal Loyer et al. JOURNAL OF BIOLOGICAL CHEMISTRY
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search